Fastox Pharma SA, a Remora company created in 2019, was acquired by AbbVie. Fastox Pharma developed a unique botulinum toxin booster technology for medical aesthetics and neurology, a ~$10 billion market, led by Abbvie’s Botox®.
The acquisition marks an important milestone for Fastox Pharma and highlights Remora Biotech’s role in enabling the development of high-quality biotherapy companies from early research through to strategic industry outcomes. It also reflects continued interest from leading pharmaceutical companies in novel technologies that complement established therapeutic platforms.
This successful transaction reinforces Remora’s proven approach to catalyze scientific innovation and turn it into clinically and commercially relevant solutions.
